Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results

Group 1 - Praxis Precision Medicines reported a wider-than-expected loss of $3.50 per share for the fourth quarter, missing the analyst consensus estimate of $3.08 per share [1] - Following the earnings announcement, Praxis Precision Medicine shares fell 0.1% to trade at $303.00 [1] Group 2 - Wedbush analyst Laura Chico maintained an Underperform rating on Praxis Precision Medicine and raised the price target from $95 to $130 [2] - Truist Securities analyst Joon Lee maintained a Buy rating and raised the price target from $500 to $700 [2] - Baird analyst Joel Beatty maintained an Outperform rating and raised the price target from $275 to $433 [2]